Nurix Therapeutics (NRIX) Competitors $9.36 -0.19 (-1.94%) As of 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. BHC, KYMR, SRRK, AMRX, XENE, CRNX, HCM, RARE, MOR, and ARWRShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), AMNEAL PHARMACEUTICALS (AMRX), Xenon Pharmaceuticals (XENE), Crinetics Pharmaceuticals (CRNX), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Its Competitors Bausch Health Cos Kymera Therapeutics Scholar Rock AMNEAL PHARMACEUTICALS Xenon Pharmaceuticals Crinetics Pharmaceuticals HUTCHMED Ultragenyx Pharmaceutical MorphoSys Arrowhead Pharmaceuticals Nurix Therapeutics (NASDAQ:NRIX) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Which has better earnings & valuation, NRIX or BHC? Bausch Health Cos has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M13.12-$193.57M-$2.61-3.59Bausch Health Cos$9.63B0.28-$46M$0.2627.52 Which has more volatility and risk, NRIX or BHC? Nurix Therapeutics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Does the media refer more to NRIX or BHC? In the previous week, Bausch Health Cos had 5 more articles in the media than Nurix Therapeutics. MarketBeat recorded 15 mentions for Bausch Health Cos and 10 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.31 beat Bausch Health Cos' score of 0.09 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch Health Cos 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate NRIX or BHC? Nurix Therapeutics currently has a consensus price target of $28.87, suggesting a potential upside of 208.24%. Bausch Health Cos has a consensus price target of $9.00, suggesting a potential upside of 25.79%. Given Nurix Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Nurix Therapeutics is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is NRIX or BHC more profitable? Bausch Health Cos has a net margin of 0.99% compared to Nurix Therapeutics' net margin of -234.57%. Nurix Therapeutics' return on equity of -45.26% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-234.57% -45.26% -34.71% Bausch Health Cos 0.99%-852.36%5.25% Do insiders & institutionals believe in NRIX or BHC? 78.7% of Bausch Health Cos shares are held by institutional investors. 7.4% of Nurix Therapeutics shares are held by company insiders. Comparatively, 8.1% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryBausch Health Cos beats Nurix Therapeutics on 9 of the 17 factors compared between the two stocks. Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$715.95M$3.06B$5.75B$9.85BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-3.5921.1531.3126.63Price / Sales13.12383.94459.79120.56Price / CashN/A44.4437.7659.36Price / Book1.268.0810.026.70Net Income-$193.57M-$54.08M$3.27B$265.68M7 Day Performance-2.95%2.44%3.26%3.46%1 Month Performance-21.50%3.56%4.45%1.11%1 Year Performance-62.67%18.78%44.34%24.00% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics2.7959 of 5 stars$9.37-1.9%$28.87+208.2%-61.2%$715.95M$54.55M-3.59300News CoveragePositive NewsAnalyst UpgradeBHCBausch Health Cos4.694 of 5 stars$8.02-3.8%$9.00+12.2%+22.1%$3.09B$9.63B30.8520,700Analyst RevisionKYMRKymera Therapeutics3.0842 of 5 stars$43.62+2.3%$59.11+35.5%-13.6%$3.05B$47.07M-12.57170News CoverageSRRKScholar Rock4.5633 of 5 stars$31.52+0.4%$45.14+43.2%+280.5%$3.02B$33.19M-10.83140AMRXAMNEAL PHARMACEUTICALS3.268 of 5 stars$9.26-2.0%$11.60+25.3%+10.4%$2.97B$2.79B926.938,100Positive NewsInsider TradeXENEXenon Pharmaceuticals2.2809 of 5 stars$37.82-1.1%$53.20+40.7%-5.0%$2.95B$9.43M-10.65210CRNXCrinetics Pharmaceuticals3.6453 of 5 stars$29.74-3.2%$68.86+131.5%-44.2%$2.89B$1.04M-7.24210News CoveragePositive NewsInsider TradeHCMHUTCHMED2.6637 of 5 stars$16.43-0.1%$28.00+70.4%-13.6%$2.87B$630.20M0.001,811RAREUltragenyx Pharmaceutical4.6665 of 5 stars$29.70+0.0%$81.50+174.4%-47.8%$2.86B$560.23M-5.371,294MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsARWRArrowhead Pharmaceuticals3.7376 of 5 stars$19.91-2.9%$43.14+116.7%-9.0%$2.84B$3.55M-15.55400Positive News Related Companies and Tools Related Companies BHC Alternatives KYMR Alternatives SRRK Alternatives AMRX Alternatives XENE Alternatives CRNX Alternatives HCM Alternatives RARE Alternatives MOR Alternatives ARWR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access